Telomir Pharmaceuticals I...

NASDAQ: TELO · Real-Time Price · USD
1.50
0.01 (0.67%)
At close: Aug 18, 2025, 3:59 PM
1.47
-2.00%
Pre-market: Aug 19, 2025, 07:05 AM EDT

Telomir Pharmaceuticals Common Stock Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a
Operating Income
-12.24M -3.94M -854.15K -138.13K
Interest Income
48K n/a n/a n/a
Pretax Income
-16.53M -13.07M -854.15K -138.13K
Net Income
-16.53M -13.07M -854.15K -138.13K
Selling & General & Admin
9.64M 600.19K 20.94K 11.64K
Research & Development
2.24M 1.57M 833.21K 126.49K
Other Expenses
n/a n/a n/a n/a
Operating Expenses
11.87M 3.94M 854.15K 138.13K
Interest Expense
-4.34M 1.64M n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
11.87M 3.94M 854.15K 138.13K
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
29.54M 29.61M 29.61M 29.61M
Shares Outstanding (Diluted)
29.54M 29.61M 29.61M 29.61M
EPS (Basic)
-0.56 -0.44 -0.03 -0.00
EPS (Diluted)
-0.56 -0.44 -0.03 -0.00
EBITDA
-12.19M -11.43M -854.15K -138.13K
EBIT
-12.19M -11.43M -854.15K -138.13K
Depreciation & Amortization
n/a -7.49M 854.15K 138.13K